INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness

Global landscape analysis identifies strengths and gaps in R&D pipeline 
to inform international pandemic preparedness efforts

ROME and CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ — The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the development of antiviral treatments to help protect the world ahead of future pandemics, today published the first phase of its global landscape assessment of antiviral research and development (R&D). Antivirals are a critical part of the world’s collective defense against new and known viruses. This research is intended to contribute to global pandemic preparedness efforts, including delivering on the 100 Days Mission set forth by the G7.

The INTREPID Alliance was formed to bring together the collective industry expertise of its members across drug discovery, antiviral R&D, and medicine manufacturing to help prioritize the most promising assets in the drug development pipeline, support their advancement and catalyze new partnerships to fill in the gaps. This landscape analysis provides an initial look at the antiviral compounds currently under investigation that target 12 viral families selected by INTREPID with the greatest pandemic potential.

Key Findings: Antiviral Clinical Development Landscape

This initial release of the INTREPID Alliance’s Antiviral Clinical Development Landscape identifies 80 clinical programs including 61 unique compounds for nine of the 12 priority viral families.1 Of the 61 compounds, 19 are approved by stringent authority or other national authority, 26 compounds are undergoing clinical phase of development from Phases 1-3. And 16 of the 61 compounds are undergoing further information gathering by INTREPID.2

Of the 26 compounds being actively developed, all but five target coronaviruses (SARS-CoV-2) and orthomyxoviruses (Influenza) with less focus on other respiratory or vector-borne viruses of concern. In addition, several of the 19 approved compounds are also being evaluated for other viral indications.

Other indications that have 1-3 compounds under development or approved include Human Adenovirus (A-G), Lassa fever, Chapare hemorrhagic fever, Ebola, Dengue, Japanese encephalitis, Crimean Congo hemorrhagic fever, Hendra virus, Rhinovirus, and Polio. Viral families with no compounds currently in clinical development are Hantaviridae, Peribunyaviridae, and Togaviridae.

The majority of the developers and sponsors of these clinical-stage compounds are from the biopharmaceutical industry with nearly 88 percent representing the spectrum of small biotechs to large pharmaceutical companies. Antiviral developers within academia follow at approximately 8 percent, contract research organizations at 3 percent, and government at approximately 2 percent.

“One of the many lessons from the COVID-19 pandemic is that we need to be better prepared, particularly related to the development of novel antiviral therapies that can help to treat the harmful impact of viruses, ease symptoms, and shorten the length of infection,” said James Anderson, Executive Director of Global Health at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Chair of the INTREPID Alliance Board. “While researchers in the industry and elsewhere continue to make progress, this landscape shows that significant gaps exist. We have the opportunity to build on the legacy of collaboration coming out of the recent pandemic to prioritize innovation in the antivirals pipeline and protect the world ahead of future pandemics.”

Coordination Across the Global Community

In support of global pandemic preparedness efforts, INTREPID leadership joined the International Pandemic Preparedness Secretariat (IPPS) today in Rome for the launch of the 100 Days Mission Therapeutics Roadmap. A cornerstone of the IPPS’s plan is the development of at least two ‘Phase 2 ready’ therapeutic candidates against the identified viral pathogen families of greatest pandemic potential.3 INTREPID’s ongoing commitment to monitor and evaluate the wide range of antiviral compounds in development through its landscape analysis will continue to provide critical data in support of this goal.

“Antiviral therapeutics are a critical component in our defense against new and emerging pandemic threats,” said Victor J. Dzau, M.D., Co-Chair of the 100 Days Mission Science and Technology Expert Group. “The INTREPID Alliance’s analysis of the current antiviral landscape will serve as a launchpad and continue to focus the global community on areas of urgent need and priority.”

Adding to this initial focus on compounds in clinical development, INTREPID is currently expanding its landscape analysis to include preclinical stage compounds. As a next step, later this year, INTREPID will publish a list of promising Phase-2 ready compounds that can be quickly deployed as antiviral compounds derived from the global landscape and scientific inspection.

To improve our listing, developers are invited to submit non-confidential information on their compound candidates through an online form at the INTREPID website. The full landscape report and data are also publicly available at the INTREPID website and will be updated quarterly.

The INTREPID Alliance actively engages with policymakers and public health bodies to ensure that antivirals are incentivized and integrated appropriately into global and local efforts to be better prepared against future pandemics.

GLOBAL DATABASE AND STUDY METHODOLOGY

The INTREPID Alliance triaged a global antiviral R&D database using stringent inclusion and exclusion criteria to arrive at the Antiviral Clinical Development Landscape. The database was licensed from Airfinity, a predictive health intelligence and data analytics firm, who monitors preclinical and clinical development of antivirals against 12 viral families that pose the greatest risk of pandemic potential. As of November 16, 2023, the Airfinity database identified 687 diverse compound/indications for the 12 priority viral families of pandemic potential; 387 were preclinical and 300 were in the clinical phase of development and/or approved by a global regulatory authority.

The triage, using inclusion and exclusion criteria, of the clinical phase and approved compound/indications identified 61 distinct antiviral compounds associated with 80 compound/indications, as reported above. Consistent with INTREPID’s mission of advancing small molecule antiviral development, compounds excluded from our analysis were antibodies, antibiotics and other anti-infectives, cell-based therapy, HIV or HCV-specific antivirals, host targets (including immunomodulators), natural products/nutraceuticals/herbals and vaccines. The triage of clinical phase compounds included small molecules, peptides, and RNA-based compounds with known direct antiviral mechanisms of action, in vitro/in vivo activity, first-in-human (FIH) single ascending dose vs. multiple ascending dose data completed and no major safety signals observed.

ABOUT THE INTREPID ALLIANCE

The INTREPID Alliance has been formed to facilitate and accelerate the development of new treatments for emerging viral pandemic agents through facilitating early science and R&D, policy and advocacy, and stakeholder engagement. Led by a consortium of innovative biopharmaceutical companies and working with the public, private and not-for-profit sectors, INTREPID works to bridge key gaps and unmet needs to ensure delivery of antiviral solutions to viral pathogens with the greatest pandemic potential.

INTREPID was launched in March 2023 at a high-level summit bringing together more than 100 thought leaders in virology and global health. For a read-out from the summit and additional information, visit www.intrepidalliance.org.

1 12 priority viral families identified by the INTREPID Alliance Scientific Working Group using the NIH/NIAID priority viral family list; World Health Organization priority disease areas; and Airfinity database of antivirals.
INTREPID Alliance: Antiviral Clinical Development Landscape. 24 January 2024.
World Health Organization priority disease areas. Accessed 24 January 2024.

SOURCE INTREPID Alliance

大灣區經濟總量超13萬億

全國政協十四屆二次會議新聞發言人劉結一表示,粵港澳大灣區經濟總量超過13萬億人民幣,成為全球最具前景的增長極之一。

尼泊爾在珠峰攀登活動中引入定位晶片

新華社北京3月4日電 隨著春季登山季臨近,尼泊爾旅遊部門要求從該國一側攀登珠峰的人租賃並使用定位晶片,以便在不測事件發生時展開搜救。

中國首個“海上風電+海洋牧場”全年上網電量將超10億千瓦時

在距離山東省萊州市海岸11公里的國家級海洋牧場示範海域,坐落著中國首個“海上風電+海洋牧場”融合發展研究試驗專案。記者從國網萊州市供電公司獲悉,這一專案2024年前兩個月上網電量達1.8485億千瓦時,全年上網電量將突破10億千瓦時。

Värde Promotes Shannon Gallagher and Tony Iannazzo to Partner

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) — Värd

CNH supports expanded rural connectivity in Latin America

CNH supports expanded rural connectivity in Latin America Th

Bitdeer Announces New 4nm Bitcoin Mining Chip SEAL01

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) — Bitdeer Techno

Quantexa Strengthens Advisory Board with the Appointment of Boon Hui Khoo

LONDON, March 04, 2024 (GLOBE NEWSWIRE) — – Quantexa, the g

相關文章

大灣區經濟總量超13萬億

全國政協十四屆二次會議新聞發言人劉結一表示,粵港澳大灣區經濟總量超過13萬億人民幣,成為全球最具前景的增長極之一。

【特刊】政府能如何更進一步?

仍然可以採取很多措施;但實際成效仍有待觀察。社會各有各說法,意見分歧。

澳門2024年GDP預計按年增一成

澳門經濟財政司司長李偉農預計2024年澳門本地生產總值(GDP)按年實質增長率可達10.3%,恢復至2019年水平約九成。

澳門1月入境旅客量恢復至疫前水平83.5%

澳門統計暨普查局資料顯示,今年1月入境旅客按年增加一倍至2,861,609人次,恢復至2019年同期83.5%。1月錄得199,278人次國際旅客,恢復至2019年同期的66.4%。

【特刊】龍年嬰兒潮:1988 年和 2012 年(2000年除外)

2000年經濟衰退期間,圍繞龍寶寶的吉祥信念並沒有成功緩解父母對生育的擔憂。

政府公佈輕軌行車系統營運36.6億元合同判給結果

澳門政府將“輕軌東線之行車系統”判予三家實體合作經營,判給金額達澳門幣36.57億元(折合約4.6 億美元)。